Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Express Scripts
Baxter
Dow
Harvard Business School

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEUPROLIDE MESYLATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for leuprolide mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00500110 ↗ Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer Completed Novartis Pharmaceuticals Phase 2 2003-06-01 Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and radical prostatectomy in high-risk localized prostate cancer. 2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor Receptor (PDGFR) pathway.
NCT00500110 ↗ Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer Completed M.D. Anderson Cancer Center Phase 2 2003-06-01 Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and radical prostatectomy in high-risk localized prostate cancer. 2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor Receptor (PDGFR) pathway.
NCT02234115 ↗ Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma Completed QPS-Qualitix Phase 3 2014-08-01 The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
NCT02234115 ↗ Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma Completed Foresee Pharmaceuticals Co., Ltd. Phase 3 2014-08-01 The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.
NCT02712320 ↗ Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg Completed QPS-Qualitix Phase 3 2016-02-01 This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.
NCT02712320 ↗ Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg Completed Foresee Pharmaceuticals Co., Ltd. Phase 3 2016-02-01 This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for leuprolide mesylate

Condition Name

Condition Name for leuprolide mesylate
Intervention Trials
Prostatic Neoplasms 3
Prostate Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for leuprolide mesylate
Intervention Trials
Prostatic Neoplasms 4
Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for leuprolide mesylate

Trials by Country

Trials by Country for leuprolide mesylate
Location Trials
United States 21
Taiwan 6
Czechia 3
Slovakia 2
Czech Republic 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for leuprolide mesylate
Location Trials
North Carolina 3
Alabama 3
Washington 2
South Carolina 2
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for leuprolide mesylate

Clinical Trial Phase

Clinical Trial Phase for leuprolide mesylate
Clinical Trial Phase Trials
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for leuprolide mesylate
Clinical Trial Phase Trials
Completed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for leuprolide mesylate

Sponsor Name

Sponsor Name for leuprolide mesylate
Sponsor Trials
QPS-Qualitix 3
Foresee Pharmaceuticals Co., Ltd. 3
M.D. Anderson Cancer Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for leuprolide mesylate
Sponsor Trials
Industry 7
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKinsey
Mallinckrodt
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.